Quetiapine: A review of its use in the treatment of bipolar depression

Drugs

Volumn 67, Issue 7, 2007, Pages 1077-1095

  Keating, Gillian M ^a   Robinson, Dean M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LAMOTRIGINE; LITHIUM; LORAZEPAM; PHENYTOIN; PLACEBO; PROLACTIN; QUETIAPINE; THIORIDAZINE; VALPROATE SEMISODIUM; VALPROIC ACID; ZOLPIDEM;

ANXIETY DISORDER; BIPOLAR DEPRESSION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; HAMILTON ANXIETY SCALE; HUMAN; MANIA; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; HUMANS;

EID: 34248369764     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767070-00008     Document Type: Review

References (57)

1. Ketter TA, Nasrallah HA, Fagiolini A. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacol Bull 2006 Winter; 39 (1): 120-46
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association, 1994
3. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl. 3: 5-69
4. Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. J Clin Psychiatry 2005; 66 Suppl. 5: 11-6
5. Altshuler LL, Gitlin MJ, Mintz J, et al. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. J Clin Psychiatry 2002 Sep; 63 (9): 807-11
6. Calabrese JR, Hirschfeld RMA, Reed M, et al. Impact of bipolar disorder on a US community sample. J Clin Psychiatry 2003 Apr; 64 (4): 425-32
7. McIntyre RS, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003; 5 (2): 20-35
8. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 53-6
9. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 Jun; 59: 530-7
10. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003 Mar; 60: 261-9
11. Calabrese JR, Elhaj O, Gajwani P, et al. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 2005; 66 Suppl. 5: 26-33
12. AstraZeneca. Seroquel® (quetiapine fumarate) tablets: prescribing information [online]. Available from URL: http://www.seroquel.com [Accessed 2007 Feb 5]
13. Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66 Suppl. 5: 40-8
14. Goldstein JM. Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwan GW, editors. Schizophrenia: breaking down the barriers. Chichester: John Wiley & Sons Ltd, 1996: 177-208
15. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia. Psychopharmacol-ogy (Berl) 1998; 135: 119-26
16. 2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001; 11: 105-10
17. Tarazi FI, Zhang K, Baldessarini RJ, et al. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002; 161: 263-70
18. 1A receptor agonism. Brain Res 2002; 956: 349-57
19. Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol 2005; 20 (4): 225-36
20. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001 Mar; 158 (3): 360-9
21. De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40 (7): 509-22
22. Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006 Jan; 61 (1): 58-69
23. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006 Mar; 21 (2): 81-5
24. Jaskiw GE, Thyrum PT, Fuller MA, et al. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clin Pharmacokinet 2004; 43 (14): 1025-35
25. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000 May; 24 (4): 521-33
26. Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001 Feb; 21 (1): 89-93
27. Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002 Apr; 22 (2): 121-30
28. Potkin SG, Thyrum PT, Bera R, et al. Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Clin Ther 2002 Nov; 24 (11): 1809-23
29. De Vane CL, Winter H, Smith MA. Open-label pharmacokinetic study of quetiapine plus divalproex in patients with schizophrenic/schizoaffective disorders or bipolar disorder [abstract no. P17]. Acta Psychiatr Scand 2004; 110 Suppl. 423: 18-9
30. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002 Apr; 22 (2): 174-82
31. Keck PE Jr, Calabrese JR, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005 Jul; 162 (7): 1351-60
32. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006 Dec; 26 (6): 600-9
33. Cookson J, Keck PE Jr, Ketter TA, et al. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007 Mar; 22 (2): 93-100
34. Hirschfeld RM, Calabrese JR, Spong E, et al. Characterization of the antidepressant effects of quetiapine in bipolar depression [poster]. 19th European College of Neuropsychopharmacology; 2006 Sep 16-20; Paris
35. Hirschfeld RMA, Weisler RH, Raines SR, et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006 Mar; 67 (3): 355-62
36. Lydiard RB, Raines S, Macfadden W, et al. Improvement in anxiety symptoms in bipolar depression with quetiapine monotherapy: results from two placebo-controlled studies [abstract no. NR691 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)
37. Endicott J, Rajagopalan K, Minkwitz M, et al. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 2007; 22 (1): 29-37
38. Macfadden W, Minkwitz M, Spong E. Quetiapine monotherapy demonstrates efficacy in reducing suicidality in bipolar depression [abstract no. NR248 plus poster]. 159th Annual Meeting of the American Psychiatric Assocation; 2006 May 20-25; Toronto (ON)
39. Weisler RH, Arvekvist R, Stening G, et al. Efficacy of quetiapine monotherapy in bipolar I depression: combined results from two double-blind, placebo-controlled studies [abstract no. NR298 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)
40. Hirschfeld R, Suppes T, Vieta E, et al. Quetiapine monotherapy for bipolar II depression: pooled results from two placebo-controlled studies [abstract no. NR227 plus poster no. NR277]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)
41. Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep 2006 Dec; 8 (6): 478-88
42. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002 Apr; 159 (4 Suppl.): 1-50
43. GM Goodwin, for the Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17 (2): 149-73
44. Keck PE Jr, Perlis RH, Otto MW, et al. The expert consensus guidelines series: treatment of bipolar disorder 2004 [online]. Available from URL: http://psychguides.com [Accessed 2007 Feb 14]
45. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 2002 Jul; 3 (3): 115-24
46. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002 Apr; 63 (4): 288-99
47. Eli Lilly and Company. Symbyax® (olanzapine and fluoxetine HCl capsules): prescribing information [online]. Available from URL: http://www.symbyax.com [Accessed 2007 Feb 14]
48. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006 Dec; 8 (6): 721-39
49. Dando TM, Keating GM. Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder. Drugs 2005; 65 (17): 2533-51
50. Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. J Clin Psychiatry 1999; 60 Suppl. 5: 5-13
51. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2007 Feb 16]
52. Milev R, Abraham G, Zaheer J. Add-on quetiapine for bipolar depression: a 12-month open-label trial. Can J Psychiatry 2006 Jul; 51 (8): 523-30
53. Hardoy MC, Garofano A, Mellino G, et al. Quetiapine as add-on treatment for bipolar I disorder: efficacy in preventing relapse of depressive episodes [abstract no. NR226 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)
54. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003 Nov; 60: 1079-88
55. American Diabetes Association, American Psychatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004 Feb; 65 (2): 267-72
56. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotics use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 2007; 27 (1): 27-35
57. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004 Jun; 65 (6): 857-63